21 Biopolis Road
No. 04-24/28 Nucleos South Building
Singapore 138567
Singapore
65 6924 6535
https://www.prestigebiopharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Ms. So-Yeon Park | Chairman & CEO | N/A | N/A | 1963 |
Mr. Lai Wat Tay | CFO & Director | N/A | N/A | 1956 |
Mr. Michael Jinwoo Kim | COO & Director | N/A | N/A | 1964 |
Ms. Chung Shii Hii | Chief Technology Officer | N/A | N/A | 1979 |
Ms. Kay K.H. Lee | Clinical Development Manager | N/A | N/A | 1970 |
Mr. Ghislain M.C Bonamy | General Manager of Licensing | N/A | N/A | 1979 |
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, first-in-class antibody drugs, and vaccines. The company primarily engages in the development of biosimilars, including Trastuzumab, which is under regulatory review for breast and gastric cancer; Bevacizumab, in phase 3 clinical study for solid tumours; Adalimumab, in phase 1 clinical study for arthritis. It is developing first-in-class antibody therapeutics, such as monoclonal antibodies, bispecific antibodies, and fusion antibodies for life-threatening diseases; vaccines for COVID-19 virus; and diagnostic kits for the detection of pancreatic adenocarcinoma upregulated factor. Prestige BioPharma Limited was incorporated in 2015 and is headquartered in Singapore.
Prestige BioPharma Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.